Seoulin Bioscience Co.Ltd Cash Flow-to-Debt Ratio
Seoulin Bioscience Co.Ltd cash flow-to-debt ratio. Seoulin Bioscience Co.Ltd (038070) has a Cash Flow-to-Debt Ratio of 0.02x as of December 2025, meaning its operating cash flow of ₩631.76 Million could theoretically repay 0% of its total liabilities (₩32.75 Billion) in one year. Check 038070 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Seoulin Bioscience Co.Ltd (2013–2025)
Cash flow-to-debt ratio of Seoulin Bioscience Co.Ltd from 2013 to 2025. Historical debt coverage capacity for Seoulin Bioscience Co.Ltd across 13 annual periods. Check how aggressively does Seoulin Bioscience Co.Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Seoulin Bioscience Co.Ltd Cash Flow-to-Debt Ratio by Year (2013–2025)
Seoulin Bioscience Co.Ltd cash flow-to-debt ratio by year from 2013 to 2025. Year-by-year debt coverage analysis for Seoulin Bioscience Co.Ltd. For the full cash flow conversion analysis, see 038070 cash generation efficiency.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.15x | ₩4.76 Billion | ₩32.75 Billion | ▲ +155.6% |
| 2024 | -0.26x | ₩-4.61 Billion | ₩17.63 Billion | ▼ -972.3% |
| 2023 | 0.03x | ₩930.57 Million | ₩31.04 Billion | ▲ +135.2% |
| 2022 | -0.09x | ₩-4.36 Billion | ₩51.08 Billion | ▼ -159.0% |
| 2021 | 0.14x | ₩8.92 Billion | ₩61.71 Billion | ▼ -28.1% |
| 2020 | 0.20x | ₩3.68 Billion | ₩18.33 Billion | ▼ -42.3% |
| 2019 | 0.35x | ₩7.32 Billion | ₩21.00 Billion | ▲ +45.3% |
| 2018 | 0.24x | ₩4.17 Billion | ₩17.39 Billion | ▲ +260.4% |
| 2017 | 0.07x | ₩1.30 Billion | ₩19.54 Billion | ▼ -56.8% |
| 2016 | 0.15x | ₩2.76 Billion | ₩17.87 Billion | ▼ -22.1% |
| 2015 | 0.20x | ₩4.12 Billion | ₩20.80 Billion | ▲ +27.0% |
| 2014 | 0.16x | ₩2.74 Billion | ₩17.57 Billion | ▼ -40.6% |
| 2013 | 0.26x | ₩4.94 Billion | ₩18.82 Billion | — |